These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 32598478)

  • 21. Striatal phosphodiesterase 10A and medial prefrontal cortical thickness in patients with schizophrenia: a PET and MRI study.
    Bodén R; Persson J; Wall A; Lubberink M; Ekselius L; Larsson EM; Antoni G
    Transl Psychiatry; 2017 Mar; 7(3):e1050. PubMed ID: 28267149
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antipsychotic-like effects of a novel phosphodiesterase 10A inhibitor T-251 in rodents.
    Takakuwa M; Watanabe Y; Tanaka K; Ishii T; Kagaya K; Taniguchi H; Kotera J; Hashimoto K
    Pharmacol Biochem Behav; 2019 Oct; 185():172757. PubMed ID: 31404565
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The PDE10A Inhibitor TAK-063 Reverses Sound-Evoked EEG Abnormalities in a Mouse Model of Fragile X Syndrome.
    Jonak CR; Sandhu MS; Assad SA; Barbosa JA; Makhija M; Binder DK
    Neurotherapeutics; 2021 Apr; 18(2):1175-1187. PubMed ID: 33594533
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of a series of novel carbon-11 labeled PDE10A inhibitors.
    Stepanov V; Miura S; Takano A; Amini N; Nakao R; Hasui T; Nakashima K; Taniguchi T; Kimura H; Kuroita T; Halldin C
    J Labelled Comp Radiopharm; 2015 May; 58(5):202-8. PubMed ID: 25891816
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Balanced Activation of Striatal Output Pathways by Faster Off-Rate PDE10A Inhibitors Elicits Not Only Antipsychotic-Like Effects But Also Procognitive Effects in Rodents.
    Harada A; Kaushal N; Suzuki K; Nakatani A; Bobkov K; Vekich JA; Doyle JP; Kimura H
    Int J Neuropsychopharmacol; 2020 Feb; 23(2):96-107. PubMed ID: 31689714
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia.
    Menniti FS; Chappie TA; Humphrey JM; Schmidt CJ
    Curr Opin Investig Drugs; 2007 Jan; 8(1):54-9. PubMed ID: 17263185
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Behavioral and qEEG effects of the PDE10A inhibitor THPP-1 in a novel rhesus model of antipsychotic activity.
    Vardigan JD; Lange HS; Tye SJ; Fox SV; Smith SM; Uslaner JM
    Psychopharmacology (Berl); 2016 Jul; 233(13):2441-50. PubMed ID: 27117142
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phosphodiesterase 2A Inhibitor TAK-915 Ameliorates Cognitive Impairments and Social Withdrawal in
    Nakashima M; Imada H; Shiraishi E; Ito Y; Suzuki N; Miyamoto M; Taniguchi T; Iwashita H
    J Pharmacol Exp Ther; 2018 Apr; 365(1):179-188. PubMed ID: 29440309
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antipsychotic-like effects of a novel phosphodiesterase 10A inhibitor MT-3014 in rats.
    Takakuwa M; Watanabe Y; Saijo T; Murata M; Anabuki J; Tezuka T; Sato S; Kojima K; Hashimoto K
    Pharmacol Biochem Behav; 2020 Sep; 196():172972. PubMed ID: 32562717
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preclinical evaluation of 18F-JNJ41510417 as a radioligand for PET imaging of phosphodiesterase-10A in the brain.
    Celen S; Koole M; De Angelis M; Sannen I; Chitneni SK; Alcazar J; Dedeurwaerdere S; Moechars D; Schmidt M; Verbruggen A; Langlois X; Van Laere K; Andrés JI; Bormans G
    J Nucl Med; 2010 Oct; 51(10):1584-91. PubMed ID: 20847170
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel 2-methoxyacylhydrazones as potent, selective PDE10A inhibitors with activity in animal models of schizophrenia.
    Cutshall NS; Onrust R; Rohde A; Gragerov S; Hamilton L; Harbol K; Shen HR; McKee S; Zuta C; Gragerova G; Florio V; Wheeler TN; Gage JL
    Bioorg Med Chem Lett; 2012 Sep; 22(17):5595-9. PubMed ID: 22841436
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Advances in the Discovery of PDE10A Inhibitors for CNS-Related Disorders. Part 2: Focus on Schizophrenia.
    Świerczek A; Jankowska A; Chłoń-Rzepa G; Pawłowski M; Wyska E
    Curr Drug Targets; 2019; 20(16):1652-1669. PubMed ID: 31368871
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pre-clinical Characterization of Absorption, Distribution, Metabolism and Excretion Properties of TAK-063.
    Tohyama K; Sudo M; Morohashi A; Kato S; Takahashi J; Tagawa Y
    Basic Clin Pharmacol Toxicol; 2018 Jun; 122(6):577-587. PubMed ID: 29345044
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of the acute oral toxicity and antipsychotic activity of a dual inhibitor of PDE1B and PDE10A in rat model of schizophrenia.
    Al-Nema M; Gaurav A; Lee MT; Okechukwu P; Nimmanpipug P; Lee VS
    PLoS One; 2022; 17(12):e0278216. PubMed ID: 36454774
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia.
    Grauer SM; Pulito VL; Navarra RL; Kelly MP; Kelley C; Graf R; Langen B; Logue S; Brennan J; Jiang L; Charych E; Egerland U; Liu F; Marquis KL; Malamas M; Hage T; Comery TA; Brandon NJ
    J Pharmacol Exp Ther; 2009 Nov; 331(2):574-90. PubMed ID: 19661377
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia.
    Schmidt CJ; Chapin DS; Cianfrogna J; Corman ML; Hajos M; Harms JF; Hoffman WE; Lebel LA; McCarthy SA; Nelson FR; Proulx-LaFrance C; Majchrzak MJ; Ramirez AD; Schmidt K; Seymour PA; Siuciak JA; Tingley FD; Williams RD; Verhoest PR; Menniti FS
    J Pharmacol Exp Ther; 2008 May; 325(2):681-90. PubMed ID: 18287214
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rapid identification of a novel small molecule phosphodiesterase 10A (PDE10A) tracer.
    Hu E; Ma J; Biorn C; Lester-Zeiner D; Cho R; Rumfelt S; Kunz RK; Nixey T; Michelsen K; Miller S; Shi J; Wong J; Hill Della Puppa G; Able J; Talreja S; Hwang DR; Hitchcock SA; Porter A; Immke D; Allen JR; Treanor J; Chen H
    J Med Chem; 2012 May; 55(10):4776-87. PubMed ID: 22548439
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of chronic antipsychotic treatment on striatal phosphodiesterase 10A levels: a [¹¹C]MP-10 PET rodent imaging study with ex vivo confirmation.
    Natesan S; Ashworth S; Nielsen J; Tang SP; Salinas C; Kealey S; Lauridsen JB; Stensbøl TB; Gunn RN; Rabiner EA; Kapur S
    Transl Psychiatry; 2014 Apr; 4(4):e376. PubMed ID: 24690597
    [TBL] [Abstract][Full Text] [Related]  

  • 39. AMG 580: a novel small molecule phosphodiesterase 10A (PDE10A) positron emission tomography tracer.
    Chen H; Lester-Zeiner D; Shi J; Miller S; Glaus C; Hu E; Chen N; Able J; Biorn C; Wong J; Ma J; Michelsen K; Hill Della Puppa G; Kazules T; Dou HH; Talreja S; Zhao X; Chen A; Rumfelt S; Kunz RK; Ye H; Thiel OR; Williamson T; Davis C; Porter A; Immke D; Allen JR; Treanor J
    J Pharmacol Exp Ther; 2015 Feb; 352(2):327-37. PubMed ID: 25502803
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phosphodiesterase 10A Inhibitor Monotherapy Is Not an Effective Treatment of Acute Schizophrenia.
    Walling DP; Banerjee A; Dawra V; Boyer S; Schmidt CJ; DeMartinis N
    J Clin Psychopharmacol; 2019; 39(6):575-582. PubMed ID: 31688451
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.